PATENT CLAIM ANALYSIS

Application Number: 16196955
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-08
Patent Classification: ["514", "300000"]

Abstract:
The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.

Claim (Index 52):
The method of  claim 50 , wherein the CDK9 inhibitor is selected from the group consisting of: flavopiridol, 4-(3,5-diamino-1H-pyrazol-4-ylazo)-phenol, 2-(pyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridinone, PHA-767491, a biaryl compound, a pyridine biaryl amine compound; a pyrimidine biaryl amine compound; an N-acyl pyrimidine biaryl compound; an N-acyl pyridine biaryl compound; a 3-(aminoaryl)-pyridine compound; a phenyl-heteroaryl amine; and salts thereof.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 98.0
- Lexical Diversity: 1.70455
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15356231', '14351878', '15517476', '10740098', '14481841']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8518522212008225
- 35 USC 102 Novelty (BERT): 0.6658129083529832
- Combined Prediction Score: 0.8332482899160385
- Mean Citation Score: 539.058552
- Max Citation Score: 740.2954
- Similarity Product: 603.005443023014

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test